Ignite Creation Date:
2025-12-25 @ 5:19 AM
Ignite Modification Date:
2025-12-26 @ 4:26 AM
Study NCT ID:
NCT00569127
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-05
First Post:
2007-12-05
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Sponsor:
National Cancer Institute (NCI)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2007-12-01
Start Date Type:
ACTUAL
Primary Completion Date:
2015-01-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-01-31
Completion Date Type:
ESTIMATED
First Submit Date:
2007-12-05
First Submit QC Date:
None
Study First Post Date:
2007-12-06
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2016-02-18
Results First Submit QC Date:
None
Results First Post Date:
2016-04-28
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-22
Last Update Post Date:
2025-12-05
Last Update Post Date Type:
ESTIMATED